Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 1, 2007AIDS

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJohn M. MurrayUNSW SydneySESean EmeryNorthampton Community CollegeAKAnthony D. KelleherUNSW Sydney

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Murray et al. (2007) studied this question.

synapsesocial.com/papers/6a8195ef916951def24cd4c2https://doi.org/10.1097/qad.0b013e3282f12377
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells2000 · 1,137 citations
  2. 2An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection.1990 · 186 citations
  3. 3Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro1995 · 197 citations
  4. 4Quantifying Residual HIV-1 Replication in Patients Receiving Combination Antiretroviral Therapy1999 · 827 citations
  5. 5Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals2006 · 366 citations